Skip to main content
News

OncoBeta’s Rhenium-SCT® for Non-Melanoma Skin Cancer to start in South Africa

TAUTOMER / NATIVA the official Rhenium-SCT® (Skin Cancer Therapy) Distributor for Continental Africa

 

OncoBeta GmbH®, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is pleased to announce that it has entered an exclusive distribution agreement with Tautomer (PTY) LTD / Nativa (PTY) LTD of South Africa to start Rhenium-SCT® (Skin Cancer Therapy) treatments in South Africa and subsequently service the African Continent. This agreement represents another milestone in the development of OncoBeta’s growing global distribution network.

TAUTOMER / NATIVA the official Rhenium-SCT® (Skin Cancer Therapy) Distributor for Continental Africa

Garching n. Munich, Germany, (June 15, 2018) – OncoBeta GmbH®, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is pleased to announce that it has entered an exclusive distribution agreement with Tautomer (PTY) LTD / Nativa (PTY) LTD of South Africa to start Rhenium-SCT® (Skin Cancer Therapy) treatments in South Africa and subsequently service the African Continent. This agreement represents another milestone in the development of OncoBeta’s growing global distribution network.

Under the terms of the agreement, Tautomer and Nativa will employ its extensive knowledge of African markets, sales and marketing expertise and strong network to introduce, distribute and service the Rhenium-SCT® therapy. The distribution agreement includes all geographies of the African continent starting with South Africa.

The initial Rhenium-SCT® treatment center in South Africa will be implemented by internationally acclaimed Nuclear Medicine Specialist Prof. Mike Sathekge of the University of Pretoria.

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Approximately 80% of non-melanoma skin cancers are basal cell carcinomas or squamous cell carcinomas. South Africa, together with Australia, has one of the highest incidence rates of basal and squamous cell carcinomas in the world.

“This partnership and cooperation is a part of our strategy to increase availability of our new and innovative skin cancer therapy to patients, especially in South Africa and beyond,” said Shannon D. Brown III, CEO and Managing Director of OncoBeta GmbH. “We look forward to making the Rhenium-SCT® more widely available to physicians and patients as we expand on this partnership and extend our reach across the African continent.”

Back